THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11016 participants.

Also called NCT03354429

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 11,016 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03354429
  • EudraCT 2016-004232-37
Other papers using this trial's data
  • Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial Stroke, 2021-07 DOI, PubMed 33940954, PMC8268075 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial JAMA neurology, 2021-09-01 DOI, PubMed 34244703, PMC8430457 In the PMC Open Access subset under CC BY-NC-ND.
  • Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack Stroke, 2021-11 DOI, PubMed 34477459, PMC8547576 In the PMC Open Access subset under CC BY.
  • Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin Stroke, 2020-12 DOI, PubMed 33198608, PMC7678660 In the PMC Open Access subset under CC BY-NC-ND.
  • Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA The New England journal of medicine, 2020-07-16 DOI, PubMed 32668111

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong SAR China, Hungary, India, Italy, Mexico, Peru, Poland, Romania, Russia, Saudi Arabia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03354429. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-22 (actual); primary completion 2019-12-13 (actual). Results posted on 2020-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Acronym
THALES
Condition
Acute Ischaemic Stroke
Condition
Transient Ischaemic Attack
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct03354429
Content hash
636c5d7496bfe0dd6d48279aff01d985fb16f2a477961378813fd9fd0a01f4a0